The Burrill Report


The Burrill Report (March 10, 2014): Expanding Access to Experimental ALS Drugs (.MP3,21.28 Mb)

Patients with the neurodegenerative disease ALS face a grim prognosis with few treatment choices. The nonprofit ALS Emergency Treatment Fund is trying to provide new alternatives to these patients through the use of so-called expanded access programs. We spoke to Jess Rabourn, managing director of the ALS Emergency Treatment Fund, about the regulations surrounding expanded access programs, how his organization gets experimental drugs into the hands of patients, and why drugmakers’ view of these programs is evolving.

March 06, 2014
http://www.burrillreport.com/article-expanding_access_to_experimental_als_drugs.html